VOR
Vor Biopharma Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Fund move
Fund move
—
No thesis.
Vor Biopharma Inc.
19.70
Largest filed tie
—
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | TCG Crossover ManagementTCG Crossover | $104.4M | 11.68% | 0.00% | |
| 2 | FMRFMR | $90.8M | 10.15% | +220.34% | |
| 3 | Fcpm III Services B.V.Fcpm III Services B.V. | $75.8M | 8.48% | 0.00% | |
| 4 | BlackRockBlackRockindex-like | $63.8M | 7.14% | +336.37% | |
| 5 | VR AdviserVR Adviser | $56.0M | 6.26% | 0.00% | |
| 6 | State StreetState Streetindex-like | $48.2M | 5.39% | +133.92% | |
| 7 | Frazier Life Sciences ManagementFrazier Life Sciences | $46.8M | 5.24% | 0.00% | |
| 8 | RA Capital ManagementRA Capital Management | $44.2M | 4.95% | −55.56% | |
| 9 | Vanguard Capital ManagementVanguardindex-like | $38.4M | 4.29% | +45.42% | |
| 10 | Caligan PartnersCaligan Partners | $35.4M | 3.96% | 0.00% | |
| 11 | Paradigm Biocapital AdvisorsParadigm Biocapital | $32.2M | 3.60% | 0.00% | |
| 12 | Great Point PartnersGreat Point Partners | $31.3M | 3.50% | −2.86% | |
| 13 | Geode Capital ManagementGeodeindex-like | $19.6M | 2.19% | +210.14% | |
| 14 | NEXTBio Capital ManagementNEXTBio | $16.4M | 1.83% | −11.08% | |
| 15 | Nantahala Capital ManagementNantahala | $15.6M | 1.74% | new | |
| 16 | ADAR1 Capital ManagementADAR1 | $12.5M | 1.40% | new | |
| 17 | Logos Global ManagementLogos Global | $12.0M | 1.34% | −13.33% | |
| 18 | Rosalind AdvisorsRosalind | $11.9M | 1.34% | −7.34% | |
| 19 | NAN Fung Trinity (hk)NAN Fung Trinity (hk) | $11.9M | 1.33% | new | |
| 20 | BraidwellBraidwell | $10.6M | 1.18% | +22.78% | |
| 21 | Boothbay Fund ManagementBoothbay Fund | $10.3M | 1.15% | +0.54% | |
| 22 | UBS GroupUBS | $9.1M | 1.02% | +1.01% | |
| 23 | Millennium ManagementMillennium | $7.9M | 0.88% | +65.54% | |
| 24 | Sphera Funds ManagementSphera Funds | $7.7M | 0.86% | +29.36% | |
| 25 | Woodline PartnersWoodline Partners | $7.0M | 0.78% | new |
102 managers report $894.2M of Vor Biopharma on form 13F for the quarter ended Jun 30 '26. 15 of them hold 80% of it; TCG Crossover is largest at 11.68%.
Expected move
No implied move.
No implied move.
No implied move.